Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026
Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026
Company Deals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

Fineline Cube Jul 7, 2026
Company Deals

Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2320 in AML

Fineline Cube Jan 21, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the first subject dosing in an...

Company Deals

Danaher Partners with Huashan Hospital to Develop Alzheimer’s Diagnostic Solutions

Fineline Cube Jan 21, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced a partnership between...

Company Drug

Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA

Fineline Cube Jan 21, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...

Company Deals

Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health

Fineline Cube Jan 21, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation...

Policy / Regulatory

NHSA Outlines 2025 Work Plan and 2024 Medical Insurance Status

Fineline Cube Jan 20, 2025

The National Healthcare Security Administration (NHSA) last week held a press conference, addressing questions regarding...

Company Drug

FDA Approves AstraZeneca’s Calquence for Mantle Cell Lymphoma

Fineline Cube Jan 20, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) last week revealed that the US Food and...

Company Deals Medical Device

NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business

Fineline Cube Jan 20, 2025

US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...

Company Drug

MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis

Fineline Cube Jan 20, 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...

Policy / Regulatory

Tianjin Healthcare Official Gao Xue Under Investigation

Fineline Cube Jan 20, 2025

Gao Xue, director of the National High-value Medical Consumables Joint Procurement Office, member of the...

Medical Device Policy / Regulatory

US BIS Imposes Export Controls on Biotech Lab Instruments

Fineline Cube Jan 20, 2025

The Department of Commerce’s Bureau of Industry and Security (BIS) of the United States last...

Company

Junshi Biosciences Forecasts 29.71% Revenue Growth for 2024

Fineline Cube Jan 20, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has released its 2024 annual...

Company Drug

FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC

Fineline Cube Jan 20, 2025

US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...

Company Drug

Luye Pharma Launches Erzofri in US Market

Fineline Cube Jan 20, 2025

China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house...

Company Drug

Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study

Fineline Cube Jan 20, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III...

Company Deals

Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain

Fineline Cube Jan 20, 2025

Xinzeyuan Medical Technology Co., Ltd, a minimally invasive surgical supply chain platform enterprise based in...

Company Drug

Zai Lab’s KarXT NDA Accepted by NMPA for Schizophrenia Treatment

Fineline Cube Jan 20, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that a New Drug...

Company Drug

Frontier Biotechnologies Gains NMPA Approval for Albuvirtide Phase II Study

Fineline Cube Jan 20, 2025

Nanjing-based Frontier Biotechnologies Inc. has announced receiving approval from the National Medical Products Administration (NMPA)...

Company Drug

Wanbangde’s Huperzine A Receives FDA Clearance for HIE Study

Fineline Cube Jan 20, 2025

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced receiving clearance from the...

Company Drug

FDA Approves Datroway for HR+/HER2- Breast Cancer Treatment

Fineline Cube Jan 20, 2025

Datroway (datopotamab deruxtecan-dlnk, Dato-Dxd), a Trop-2-directed antibody and topoisomerase inhibitor conjugate co-developed by Japan-based Daiichi...

Company Drug

Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study

Fineline Cube Jan 20, 2025

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd has announced receiving approval from the National Medical Products...

Posts pagination

1 … 249 250 251 … 691

Recent updates

  • China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
  • Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development
  • Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio
  • Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project
  • CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.